RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, announced today its continued participation in the ALS Association-sponsored study to identify biomarkers of amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease). The Company participated in the initial pilot study, resulting in the discovery of novel biomarkers indicative of ALS and covered by a recently issued patent (US Patent 7,005,255). The expanded study will increase study enrollment. Samples will be collected at 18 sites in the Translational Research Advancing Therapy for ALS (TREAT ALS)/Northeast ALS (NEALS) Clinical Trials Network. The Network is a partnership between The ALS Association and NEALS clinical research centers throughout the country, devoted to expanding clinical trials to treat the disease.
